ERBB2 and breast cancer: The EMILIA study, a pivotal phase III clinical study of T-DM1 for the second-line treatment of advanced HER2-positive BC, showed that T-DM1 significantly prolonged the median PFS and median OS with lower toxicity and better overall tolerability than lapatinib combined with capecitabine in HER2-positive advanced BC patients previously treated with paclitaxel and trastuzumab-based agents (60).